Plain-English translation of NCT07328087 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new personalized cancer vaccine called COLONYVAQ-CRC, designed specifically for each patient based on their tumor's unique mutations. You would receive this vaccine alongside standard chemotherapy (oxaliplatin-based drugs) and nivolumab, a drug that helps your immune system fight cancer cells. The goal is to reduce the chance that your colon cancer returns after surgery.
Most people with stage III colon cancer still face a high risk of the cancer coming back, even after surgery and standard chemotherapy. This medication is designed to help your body's immune system recognize and attack any remaining cancer cells that might be hiding in your body, potentially preventing recurrence.
You likely qualify if…
You likely don't qualify if…
After your surgery, you would receive standard chemotherapy for about 3–6 months, along with the personalized vaccine injected under your skin at set intervals (starting with multiple doses in the first month, then spaced further apart). You would also receive nivolumab infusions every 2 weeks for up to 12 months. You would have regular clinic visits to receive these treatments and monitor your health with blood tests and scans.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Greece